Clinical and experimental study on regional administration of phosphorus 32 glass microspheres in treating hepatic carcinoma

Table 1 Nude mice in different absorbed dosage group the tumor weight (g) variance, SNK analysis and tumor inhibiting rate (14 d)

Group	No. of Cases (n)	Tumor weight① (-x±s)	SNK②	Absorbed dose mean value (Gy)	Tumor inhibiting rate (%)	Necrosed tumor cell (%)
Control	8	6.25 ± 0.39	A	-	-	4
I	6	0.40 ± 0.10a	B	7320	93.6	82
II	6	0.46 ± 0.08a	B	3660	92.5	78
III	8	0.94 ± 0.10a	C	1830	84.8	70
IV	6	2.17 ± 0.26a	D	366	65.3	47
V	6	2.43 ± 0.33a	E	183	59.7	40

①Variance analysis of the mean tumor weight of different doses and control group after square root correction, F = 579.62,

^aP < 0.01. ② Different or same alphabets denote with or without statistical signific ance of mean deviations between groups respectively.

Table 2 Relationship between tumor inhibiting rate and execution time in tumor-bearing nude mice accepted ³²P-GMS in absorbed dose of 366Gy

Time of execution (d)	Weight of tumor (g) treatment group/control group	Tumor inhibiting rate (%)
3	1.5/2.3	34.8
6	1.7/3.2	46.9
13	2.1/5.9	64.4
20	1.6/6.7	76.1
28	1.0/6.8	85.3

Table 3 Histological liver tissue parameter and estimated value of a bsorbed dose in domestic pigs with hepatic arterial administration of ³² P-GMS

Animal serial No.	Sex	Route of medication	Time of death (wk)	32P-GMS (MPq·mg-1)			Tissue macrocosmic mean absorbed dose (Gy)
				Administered activity (MBq)	Cumulated activity (MBq)	Weight (mg)
1	F	Right hepatic artery	1	0	0	300
2	M	Left hepatic artery	2	0	0	260
3	F	Hepatic artery proper	4	0	0	1353
4	M	Hepatic artery proper	8	0	0	374
5	F	Right hepatic artery	16	0	0	1000
6	M	Right hepatic artery	1	925	266	313	48
7	F	Left hepatic artery	2	944	465	705	190
8	M	Hepatic artery proper	4	1070	825	375	104
9	F	Left hepatic artery	8	459	529	343	136
10	M	Right hepatic artery	16	461	459	349	61△
11	F	Hepatic artery proper	16	0		0
12	M	Hepatic artery proper	16	0		0

△Calculated from the estimated liver weight of 1.5 kg before medication.

Table 4 N_abn and M_var of nucleated hepatocytes and their standard error (P±SE)

No. of week	Warm sphere group		Cold sphere group		Bland control
	Nabn	Mvar	Nabn	Mvar	Nabn	Mvar
1	60 ± 4.09a	80 ± 4.00a	9 ± 2.86c	5 ± 2.18c
2	58 ± 4.94a	77 ± 4.21a	8 ± 2.71c	4 ± 1.96c
4	38 ± 4.85b	60 ± 4.90b	5 ± 2.18c	6 ± 2.37c
8	8 ± 2.71cd	12 ± 3.25ce	3 ± 1.71c	5 ± 2.18c
16	4 ± 1.96cd	4 ± 1.40ce	2 ± 1.40c	2 ± 1.96c	2 ± 1.40	2 ± 1.40

Warm sphere group no statistical significance between week 1 and week 2, χ² = 0.27,

^aP < 0.50. In warm sphere group comparison of week 1 and week 2 with week 4, χ² = 6.70-9.68,

^bP < 0.01 and with other groups, χ² = 65.09-115.09,

^cP < 0.001. N_abn of week 8 compared with that of week 16, χ² = 1.42,

^dP < 0.20. M_var of week 8 compared with that of week 16, χ² = 7.68,

^eP < 0.01.

Table 5 Comparison of effectiveness in different therapeutic groups

Grade of effectiveness	Group A	Group B( n )	Group C
> 50%	9	15	4
50%-25%	7	18	5
25%-10%	9	13	5
< 10%	5	3	4
Effective rate %	83.33	93.87	77.77

RIDIT analysis: A/C: α≠ 0.05, no statistical diff erence between two groups. B/C: α = 0.05, significant difference between t wo groups.

Table 6 Comparison of toxic hematological reaction in different groups

Grading	Group A ( n )			Group B ( n )			Group C ( n )
	Hb	WBC	Plt	Hb	WBC	Plt	Hb	WBC	Plt
0	10	12	12	1 8	15	16	2	4	2
I	12	16	10	2 2	24	23	5	2	4
II	8	2	8	7	8	9	6	6	6
III				2	2	1	3	4	3
IV							2	2	3